Page last updated: 2024-10-16

adenine and B-Cell Lymphoma

adenine has been researched along with B-Cell Lymphoma in 54 studies

Research Excerpts

ExcerptRelevanceReference
" Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma."3.83Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. ( Barassi, C; Bernasconi, E; Bertoni, F; Cascione, L; Gaudio, E; Goodstal, S; Kwee, I; Ponzoni, M; Rinaldi, A; Stathis, A; Tarantelli, C; Targa, A; Zucca, E, 2016)
" The most common (≥ 20% patients) adverse events were neutropenia, anemia, nasopharyngitis, increased bilirubin, and rash."2.82Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. ( Aoki, T; Ishizawa, K; Morishita, T; Munakata, W; Ogura, M; Suzuki, T; Takahara, S; Tobinai, K; Uchida, T; Ushijima, Y, 2016)
" Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas."2.61Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019)
" In a recently published phase 3 trial (RESONATE) that compared ibrutinib and ofatumumab for the treatment of relapsed and refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, ibrutinib at the daily dosage of 420 mg demonstrated a significantly higher overall response rate (43% in ibrutinib vs."2.53A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. ( Kim, SS; Lee, CS; Rattu, MA, 2016)
" Analysis of anti-CD20 mediated activation of natural killer cells isolated from patients on continued oral ibrutinib treatment suggested that repeated drug dosing inhibits these cells in vivo."1.42Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. ( Beurskens, FJ; Breij, EC; Da Roit, F; Engelberts, PJ; Golay, J; Gritti, G; Introna, M; Parren, PW; Rambaldi, A; Taylor, RP, 2015)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's41 (75.93)24.3611
2020's13 (24.07)2.80

Authors

AuthorsStudies
Malfona, F1
Testi, AM1
Moleti, ML1
Petrucci, L1
Leccisotti, L1
Martelli, M1
Di Rocco, A1
Bories, P1
Ysebaert, L1
Tahir, F1
Sy, J1
Reddel, S1
Trotman, J4
Castillo, JJ3
Buske, C3
Sarosiek, S3
Treon, SP4
Nierengarten, MB1
Ball, S1
Das, A1
Vutthikraivit, W1
Edwards, PJ1
Hardwicke, F1
Short, NJ1
Borthakur, G1
Maiti, A1
Jordaens, S1
Cooksey, L1
Bonney, S1
Orchard, L1
Coutinho, M1
Van Tendeloo, V1
Mills, KI1
Orchard, K1
Guinn, BA1
Burke, GAA1
Beishuizen, A1
Bhojwani, D1
Burkhardt, B1
Minard-Colin, V1
Norris, RE1
Kabickova, E1
Pinarli, FG1
Tacyildiz, N1
Howes, A1
Jong, J1
Liu, G1
Nottage, K1
Salman, M1
Trixhe, XW1
Cairo, M1
Terao, T1
Narita, K1
Tsushima, T1
Miura, D1
Takeuchi, M1
Matsue, K1
Chong, EA1
Roeker, LE1
Shadman, M1
Davids, MS1
Schuster, SJ2
Mato, AR1
Beauchamp, E1
Yap, MC1
Iyer, A1
Perinpanayagam, MA1
Gamma, JM1
Vincent, KM1
Lakshmanan, M1
Raju, A1
Tergaonkar, V1
Tan, SY1
Lim, ST1
Dong, WF1
Postovit, LM1
Read, KD1
Gray, DW1
Wyatt, PG1
Mackey, JR1
Berthiaume, LG1
Matissek, SJ1
Han, W1
Karbalivand, M1
Sayed, M1
Reilly, BM1
Mallat, S1
Ghazal, SM1
Munshi, M1
Yang, G1
Walker, SR1
Elsawa, SF1
Liu, M1
Deng, H1
Mu, J1
Li, Q1
Pu, Y1
Jiang, Y1
Deng, Q1
Qian, Z1
Ping, L2
Ding, N3
Shi, Y2
Feng, L2
Li, J1
Liu, Y2
Lin, Y1
Shi, C1
Wang, X2
Pan, Z3
Song, Y3
Zhu, J2
Barr, PM1
Göckeritz, E1
Vondey, V1
Guastafierro, A1
Pizevska, M1
Hassenrück, F1
Neumann, L1
Hallek, M2
Krause, G1
Thorp, BC1
Badoux, X1
de Weerdt, I1
Koopmans, SM1
Kater, AP1
van Gelder, M1
Shah, B1
Zhao, X2
Silva, AS1
Shain, KH1
Tao, J1
Brown, JR1
Zhang, Z1
Zhang, D1
Yang, D1
Ran, F1
Wang, ML2
Zhao, G1
Sun, Y1
Gao, H1
Wu, Y1
Yang, Y1
Zhao, M1
Hwang, J1
Liu, W1
Rao, Y1
Beauvais, D1
Goossens, JF1
Boyle, E1
Allal, B1
Lafont, T1
Chatelut, E1
Herbaux, C1
Morschhauser, F1
Genay, S1
Odou, P1
Danel, C1
Shaikh, H1
Khattab, A1
Faisal, MS1
Chilkulwar, A1
Albrethsen, M1
Sadashiv, S1
Fazal, S1
McCarter, SJ1
Vijayvargiya, P1
Sidana, S1
Nault, AM1
Lane, CE1
Lehman, JS1
Wilson, JW1
Parikh, SA1
Nowakowski, GS1
Al-Kali, A1
da Cunha-Bang, C1
Niemann, CU1
Ganatra, S1
Sharma, A1
Shah, S1
Chaudhry, GM1
Martin, DT1
Neilan, TG1
Mahmood, SS1
Barac, A1
Groarke, JD1
Hayek, SS1
Dani, S1
Venesy, D1
Patten, R1
Nohria, A1
Landsburg, DJ1
Hughes, ME1
Koike, A1
Bond, D1
Maddocks, KJ1
Guo, L1
Winter, AM1
Hill, BT1
Ondrejka, SL1
Hsi, ED1
Nasta, SD1
Svoboda, J1
Bogusz, AM1
Tarantelli, C2
Zhang, L1
Curti, E1
Gaudio, E2
Spriano, F1
Priebe, V1
Cascione, L2
Arribas, AJ1
Zucca, E2
Rossi, D1
Stathis, A2
Bertoni, F2
Nguyen, PH1
Niesen, E1
Geyer, MB1
Rivière, I1
Sénéchal, B1
Wang, Y2
Purdon, TJ1
Hsu, M1
Devlin, SM1
Palomba, ML1
Halton, E1
Bernal, Y1
van Leeuwen, DG1
Sadelain, M1
Park, JH1
Brentjens, RJ1
Bukhari, A1
El Chaer, F1
Koka, R1
Singh, Z1
Hutnick, E1
Ruehle, K1
Lee, ST1
Kocoglu, MH1
Shanholtz, C1
Badros, A1
Hardy, N1
Yared, J1
Rapoport, AP1
Dahiya, S1
Aalipour, A1
Advani, RH2
Akinleye, A1
Furqan, M1
Adekunle, O1
Maddocks, K1
Blum, KA2
Kohrt, HE1
Sagiv-Barfi, I1
Rafiq, S1
Herman, SE1
Butchar, JP1
Cheney, C1
Zhang, X1
Buggy, JJ3
Muthusamy, N1
Levy, R1
Johnson, AJ1
Byrd, JC1
Sehgal, L1
Mathur, R1
Braun, FK1
Wise, JF1
Berkova, Z1
Neelapu, S1
Kwak, LW1
Samaniego, F1
Da Roit, F1
Engelberts, PJ1
Taylor, RP1
Breij, EC1
Gritti, G1
Rambaldi, A1
Introna, M1
Parren, PW1
Beurskens, FJ1
Golay, J1
Lee, CS1
Rattu, MA1
Kim, SS1
Zhang, LL1
Champlin, RE1
Alinari, L1
Quinion, C1
Li, X1
Wu, L1
Fu, K1
Zheng, X1
Oh, PS1
Hwang, H1
Jeong, HS1
Kwon, J1
Kim, HS1
Kim, M1
Lim, S1
Sohn, MH1
Jeong, HJ1
Tobinai, K1
Ogura, M1
Ishizawa, K1
Suzuki, T1
Munakata, W1
Uchida, T1
Aoki, T1
Morishita, T1
Ushijima, Y1
Takahara, S1
Kwee, I1
Barassi, C1
Bernasconi, E1
Rinaldi, A1
Ponzoni, M1
Targa, A1
Goodstal, S1
Roskoski, R1
Ruella, M1
Kenderian, SS1
Shestova, O1
Klichinsky, M1
Melenhorst, JJ1
Wasik, MA1
Lacey, SF1
June, CH1
Gill, S1
Kreiniz, N1
Bejar, J1
Polliack, A1
Tadmor, T1
Alfaro, J1
Pérez de Arce, F1
Belmar, S1
Fuentealba, G1
Avila, P1
Ureta, G1
Flores, C1
Acuña, C1
Delgado, L1
Gaete, D1
Pujala, B1
Barde, A1
Nayak, AK1
Upendra, TVR1
Patel, D1
Chauhan, S1
Sharma, VK1
Kanno, S1
Almirez, RG1
Hung, DT1
Chakravarty, S1
Rai, R1
Bernales, S1
Quinn, KP1
Pham, SM1
McCullagh, E1
Honigberg, LA1
Smith, AM1
Sirisawad, M1
Verner, E1
Loury, D1
Chang, B1
Li, S1
Thamm, DH1
Miller, RA1
Ireland, JM1
Unanue, ER1
Harrison, C1
Sharman, JP1
Smith, SM1
Boyd, TE1
Grant, B1
Kolibaba, KS1
Furman, RR1
Rodriguez, S1
Chang, BY1
Sukbuntherng, J1
Izumi, R1
Hamdy, A1
Hedrick, E1
Fowler, NH1
Wiestner, A1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Trial of PCLX-001 in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies[NCT04836195]Phase 160 participants (Anticipated)Interventional2021-09-14Recruiting
Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235]50 participants (Anticipated)Interventional2022-11-01Recruiting
A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531]Phase 1/Phase 250 participants (Actual)Interventional2007-03-21Active, not recruiting
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798]Phase 322 participants (Actual)Interventional2019-12-09Active, not recruiting
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms[NCT01704963]Phase 115 participants (Actual)Interventional2012-09-12Completed
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654]Phase 166 participants (Actual)Interventional2009-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Reviews

18 reviews available for adenine and B-Cell Lymphoma

ArticleYear
[Chimeric antigen receptor T cells].
    Bulletin du cancer, 2021, Volume: 108, Issue:10S

    Topics: Adenine; Antibodies, Bispecific; Antigens, CD19; Antigens, Neoplasm; Cell Engineering; Clinical Tria

2021
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    American journal of hematology, 2023, Volume: 98, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase

2023
Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:2

    Topics: Adenine; Humans; Lymphoma, B-Cell; Piperidines; Randomized Controlled Trials as Topic; Risk

2020
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:2

    Topics: Adenine; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Clinical Trials as Topic; Disea

2018
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
    Haematologica, 2017, Volume: 102, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Disease Management; Drug Intera

2017
Resistance to Ibrutinib in B Cell Malignancies: One Size Does Not Fit All.
    Trends in cancer, 2018, Volume: 4, Issue:3

    Topics: Adenine; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Piperi

2018
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Archiv der Pharmazie, 2018, Volume: 351, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; B

2018
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:5

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi

2019
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    Drugs, 2018, Volume: 78, Issue:16

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Benzamides; Drug

2018
Ibrutinib-Associated Atrial Fibrillation.
    JACC. Clinical electrophysiology, 2018, Volume: 4, Issue:12

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrial Fibrillation; Female; Humans;

2018
New roles for B cell receptor associated kinases: when the B cell is not the target.
    Leukemia, 2019, Volume: 33, Issue:3

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Humans; Lymphoma, B-Cell; Pipe

2019
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
    British journal of haematology, 2013, Volume: 163, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Humans; Lymphoma, B-Cell; Molecular Targeted

2013
Ibrutinib and indolent B-cell lymphomas.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top

2014
Ibrutinib in B-cell Lymphomas.
    Current treatment options in oncology, 2014, Volume: 15, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Clin

2014
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:1

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Disease-Free Survival; Human

2016
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans

2015
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
    Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans

2015
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Pharmacological research, 2016, Volume: 113, Issue:Pt A

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Humans; Lymphoma, B-Cell; Piperidines;

2016

Trials

3 trials available for adenine and B-Cell Lymphoma

ArticleYear
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    JCI insight, 2019, 04-02, Volume: 5

    Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2019
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
    International journal of hematology, 2016, Volume: 103, Issue:1

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Asian People; Enzy

2016
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over;

2013

Other Studies

33 other studies available for adenine and B-Cell Lymphoma

ArticleYear
Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Leukemia & lymphoma, 2022, Volume: 63, Issue:2

    Topics: Adenine; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma; Lymphoma, B-Cel

2022
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:6

    Topics: Adenine; Aged; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukoencephalopathy, Progressive Mult

2022
New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer, 2023, 11-01, Volume: 129, Issue:21

    Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Recurrence

2023
Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    British journal of haematology, 2020, Volume: 189, Issue:3

    Topics: Adenine; Adult; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Piperidines; Precursor B-Cell L

2020
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
    Leukemia, 2020, Volume: 34, Issue:8

    Topics: Adenine; Adolescent; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Immunothera

2020
Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:7

    Topics: Adenine; Adult; Humans; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Piperidines; SOXC Transcription Fac

2020
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-15, Volume: 26, Issue:14

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benza

2020
Targeting N-myristoylation for therapy of B-cell lymphomas.
    Nature communications, 2020, 10-22, Volume: 11, Issue:1

    Topics: Acyltransferases; Adenine; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tum

2020
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
    Epigenomics, 2021, Volume: 13, Issue:2

    Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesi

2021
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Cancer science, 2021, Volume: 112, Issue:7

    Topics: Adenine; Adult; Aged; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Fem

2021
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
    Oncotarget, 2017, Jun-13, Volume: 8, Issue:24

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chem

2017
Efficacy in the margins of NHL with ibrutinib.
    Blood, 2017, 04-20, Volume: 129, Issue:16

    Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Pyrazole

2017
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    British journal of haematology, 2017, Volume: 178, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Chemokines; Chem

2017
Ibrutinib: coming of age?
    Blood, 2018, 04-26, Volume: 131, Issue:17

    Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines; Pyraz

2018
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
    Cell research, 2018, Volume: 28, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; HEK293 Cells; HeLa Cells; H

2018
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2018, Sep-01, Volume: 1093-1094

    Topics: Adenine; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Lymphoma, B-Cell; Piperid

2018
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:2

    Topics: Abscess; Adenine; Antifungal Agents; Aspergillosis; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Orga

2019
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
    Blood advances, 2019, 01-22, Volume: 3, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance,

2019
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica, 2019, Volume: 104, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge

2019
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.
    American journal of hematology, 2019, Volume: 94, Issue:10

    Topics: Adenine; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Pro

2019
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
    Blood, 2014, Mar-20, Volume: 123, Issue:12

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antibodies, Monoclonal, Murine-Derived; Antib

2014
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.
    Leukemia, 2014, Volume: 28, Issue:12

    Topics: Adenine; Alternative Splicing; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DN

2014
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
    Haematologica, 2015, Volume: 100, Issue:1

    Topics: Adenine; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antineoplasti

2015
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Apoptosis

2015
Blue light emitting diode induces apoptosis in lymphoid cells by stimulating autophagy.
    The international journal of biochemistry & cell biology, 2016, Volume: 70

    Topics: Adenine; Animals; Apoptosis; Autophagy; B-Lymphocytes; bcl-2-Associated X Protein; Caspase 3; Cell L

2016
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Line, Tumor; Class I Phosphatidylinosito

2016
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.
    Leukemia, 2017, Volume: 31, Issue:1

    Topics: Adenine; Animals; Antibodies; Antigens, CD19; Cytokines; Heterografts; Humans; Lymphoma, B-Cell; Mic

2017
Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
    Hematological oncology, 2018, Volume: 36, Issue:1

    Topics: Adenine; Aged; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Piperidines

2018
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
    The Journal of pharmacology and experimental therapeutics, 2017, Volume: 361, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; B-Lymphocytes; Cell De

2017
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Jul-20, Volume: 107, Issue:29

    Topics: Adenine; Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental

2010
Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells.
    The Journal of experimental medicine, 2011, Dec-19, Volume: 208, Issue:13

    Topics: Adenine; Animals; Antigen Presentation; Antigen-Presenting Cells; Autophagy-Related Protein 5; B-Lym

2011
Trial watch: BTK inhibitor shows positive results in B cell malignancies.
    Nature reviews. Drug discovery, 2012, Jan-20, Volume: 11, Issue:2

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Lymphoma, B-Cell; Piper

2012
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Prognosis; Prot

2013